Your browser doesn't support javascript.
loading
Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies.
Hu, Xingsheng; Zhang, Shucai; Ma, Zhiyong; Feng, Jifeng; Wu, Lin; Lv, Dongqing; Zhou, Jianying; Zhang, Xiaodong; Liu, Li; Yu, Qitao; Liao, Wangjun; Zhang, Yiping; Wang, Xiang; Cheng, Ying; Niu, Hongrui; Wang, Ziping; Wang, Dong; Huang, Cheng; Liu, Chunling; Zhao, Hui; Feng, Jian; Li, Jingzhang; Ying, Kejing; Yang, Nong; Qin, Shukui; Hu, Jie; Liu, Fei; Jiang, Yong; Ge, Nan; Shi, Yuankai.
Afiliação
  • Hu X; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, Beijing, 100021, China.
  • Zhang S; Department of Oncology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Oncology Institute, Beijing, China.
  • Ma Z; Department of Medical Oncology, Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, Zhengzhou, China.
  • Feng J; Department of Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, China.
  • Wu L; Thoracic Medicine Department II, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
  • Lv D; Department of Respiratory Medicine, Taizhou Hospital of Zhejiang Province, Taizhou, China.
  • Zhou J; Department of Respiratory Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Zhang X; Department of Medical Oncology, Nantong Cancer Hospital, Nantong, China.
  • Liu L; Department of Thoracic Oncology, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Yu Q; Department of Respiratory Oncology, Guangxi Medical University Affiliated Tumor Hospital, Nanning, China.
  • Liao W; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Zhang Y; Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
  • Wang X; Department of Medical Oncology, Xuzhou Central Hospital, Xuzhou, China.
  • Cheng Y; Department of Oncology, Jilin Cancer Hospital, Changchun, China.
  • Niu H; Department of Oncology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China.
  • Wang Z; Department of Thoracic Medical Oncology, Peking University Cancer Hospital and Institute, Beijing, China.
  • Wang D; Department of Oncology, Army Medical Centre of People's Liberation Army, Chongqing, China.
  • Huang C; Department of Oncology, Fujian Cancer Hospital, Fuzhou, China.
  • Liu C; Department of Pulmonary Medicine, Cancer Hospital of Xinjiang Medical University, Urumqi, China.
  • Zhao H; Department of Respiratory and Critical Care Medicine, The Second Hospital of Anhui University, Hefei, China.
  • Feng J; Department of Respiratory Medicine, Affiliated Hospital of Nantong University, Nantong, China.
  • Li J; Department of Oncology, Liuzhou People's Hospital, Liuzhou, China.
  • Ying K; Department of Respiratory Medicine, Sir Run Shaw Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, China.
  • Yang N; Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
  • Qin S; The People's Liberation Army Cancer Center, Jinling Hospital, Nanjing, China.
  • Hu J; Shanghai Allist Pharmaceutical Technology Co., Ltd, , Shanghai, China.
  • Liu F; Shanghai Allist Pharmaceutical Technology Co., Ltd, , Shanghai, China.
  • Jiang Y; Shanghai Allist Pharmaceutical Technology Co., Ltd, , Shanghai, China.
  • Ge N; Shanghai Allist Pharmaceutical Technology Co., Ltd, , Shanghai, China.
  • Shi Y; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, Beijing, 100021, China. syuank
BMC Med ; 21(1): 164, 2023 04 28.
Article em En | MEDLINE | ID: mdl-37118803
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Tipo de estudo: Systematic_reviews Limite: Humans Idioma: En Revista: BMC Med Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Tipo de estudo: Systematic_reviews Limite: Humans Idioma: En Revista: BMC Med Ano de publicação: 2023 Tipo de documento: Article